Intersection of inflammation and herbal medicine in the treatment of osteoarthritis

Current Rheumatology Reports

Volumn 14, Issue 6, 2012, Pages 604-616

  Mobasheri, Ali ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Articular cartilage; Ayurvedic medicine; Catechins; Clinical trials; Ethnopharmacology; Flavonoids; Herbal medicine; Inflammation; Mesenchymal stem cell; Musculoskeletal complaints; Nutrigenomics; Osteoarthritis; Phytochemicals; Rheumatic diseases; Synovium; Treatment

Indexed keywords

ANTIOXIDANT; BOIOGITO; CAESALPINIA SAPPAN EXTRACT; CHINESE DRUG; CURCUMIN; DEXAMETHASONE; DIACEREIN; DICLOFENAC; DUHUO JISHENG WAN; FLAVOCOXID; GINGER EXTRACT; HARPAGOPHYTUM PROCUMBENS EXTRACT; HERBACEOUS AGENT; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LOXOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PG 201; PLACEBO; PLANT EXTRACT; RESVERATROL; ROFECOXIB; ROSA CANINA EXTRACT; SALIX ALBA EXTRACT; SKI 306X; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URTICA DIOICA EXTRACT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AYURVEDA; CARTILAGE CELL; CELL PROTECTION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ETHNOPHARMACOLOGY; HEALTH SURVEY; HERBAL MEDICINE; HIP OSTEOARTHRITIS; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; JOINT EFFUSION; KNEE ARTHRITIS; KNEE OSTEOARTHRITIS; MEDICINAL PLANT; MESENCHYMAL STEM CELL; NONHUMAN; NUTRIGENOMICS; OSTEOARTHRITIS; PATHOGENESIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; ROSA CANINA; SALIX ALBA; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT;

HUMANS; INFLAMMATION; OSTEOARTHRITIS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 84869233544     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0288-9     Document Type: Review

References (85)

1. The United Nations (UN). 2012. http: //www.un.org/en/. Accessed July 2012
2. The World Health Organization (WHO). 2012. http: //www.who.int/ en/. Accessed July 2012
3. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003; 81(9): 646-56. (Pubitemid 37254686)
4. Symmons D,Mathers C, Pfleger B. Global burden of osteoarthritis in the year 2000. World Health Organization (WHO). 2000. http: // www.who.int/ healthinfo/statistics/bod-osteoarthritis.pdf. Accessed July 2012
5. Ehrlich GE. The rise of osteoarthritis. Bull World Health Organ. 2003; 81(9): 630. (Pubitemid 37254682)
6. The Arthritis Foundation (AF). 2012. http: //www.arthritis.org/. Accessed July 2012
7. Aigner T, Rose J, Martin J, Buckwalter J. Aging theories of primary osteoarthritis: fromepidemiology tomolecular biology. Rejuvenation Res. 2004; 7(2): 134-45. doi: 10.1089/1549168041552964. (Pubitemid 39150064)
8. Centers for Disease Control and Prevention (CDC). 2012. http: // www.cdc.gov/. Accessed July 2012
9. National Institute of Arthritis andMusculoskeletal and Skin Diseases (NIAMS). 2012. http: //www.niams.nih.gov/. Accessed July 2012
10. Lotz MK, Kraus VB. New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options. Arthritis Res Ther. 2010; 12(3): 211. doi: 10.1186/ar3046.
11. Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010; 69(4): 761-5. doi: 10.1136/ard.2008.106930.
12. Buckwalter JA, Mankin HJ, Grodzinsky AJ. Articular cartilage and osteoarthritis. Instr Course Lect. 2005; 54: 465-80.
13. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007; 213(3): 626-34. doi: 10.1002/jcp.21258. (Pubitemid 350058254)
14. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010; 6(11): 625-35. doi: 10.1038/nrrheum.2010.159.
15. International Society for Ethnopharmacology. 2012. http: // www.ethnopharmacology.org/ Accessed July 2012
16. Journal of Ethnopharmacology. 2012. http: //www.journals. elsevier.com/journal-of-ethnopharmacology/. Accessed July 2012
17. Frontiers in Ethnopharmacology. 2012. http: //www.frontiersin.org/ Ethnopharmacology. Accessed July 2012
18. U.S. Food and Drug Administration (FDA). 2012. http: // www.fda.gov/. Accessed July 2012
19. Use Caution With Ayurvedic Products. FDA Consumer Health Information. 2012. http: //www.fda.gov/downloads/ForConsumers/ ConsumerUpdates/ucm050819.pdf. Accessed July 2012
20. van Ommen B, Stierum R. Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr Opin Biotechnol. 2002; 13(5): 517-21. (Pubitemid 35379941)
21. van Ommen B. Nutrigenomics: exploiting systems biology in the nutrition and health arenas. Nutrition. 2004; 20(1): 4-8. (Pubitemid 38091572)
22. van Ommen B. Personalized nutrition from a health perspective: luxury or necessity? Genes Nutr. 2007; 2(1): 3-4. doi: 10.1007/ s12263-007-0018-5.
23. van Ommen B, Keijer J, Heil SG, Kaput J. Challenging homeostasis to define biomarkers for nutrition related health. Mol Nutr Food Res. 2009; 53(7): 795-804. doi: 10.1002/mnfr.200800390. This important paper discusses strategies, and technology for measuring variables that define an individual's health. The authors describe concepts that are central to defining the physiology of the healthy individual. They warn that the effects of nutritional intervention may remain hidden unless new strategies and biomarkers are developed to study nutrition-related health and prevent disease through improved nutrition.
24. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006; 8(6): R187. doi: 10.1186/ar2099. (Pubitemid 46211006)
25. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci. 1999; 4: D694-703.
26. Sadouk MB, Pelletier JP, Tardif G, Kiansa K, Cloutier JM, Martel-Pelletier J. Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest. 1995; 73(3): 347-55.
27. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NFkappaB signaling: multiple angles to target OA. Curr Drug Targets. 2010; 11(5): 599-613. This review article summarizes the central function of activated NF-κ B in response to pro-inflammatory cytokines, excessive mechanical stress, and ECM degradation products in chondrocytes. Activated NF-κ B also regulates the expression of chemokines, adhesion molecules, and several matrix-degrading enzymes. The authors propose that NF-κ B-activating kinases are potential therapeutic OA targets. Therefore, strategies that prevent excessive NF-κ B activation in this context may be used to treat inflammatory joint diseases. Furthermore, exclusive targeting of such strategies at affected cartilage and joints can avoid undesirable systemic effects of NF-κ B inhibition.
28. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets. 2009; 10(12): 1245-54.
29. Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? - a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2008; 16(9): 965-72. doi: 10.1016/ j.joca.2008.03.001.
30. Rosehip Powder for Knee Osteoarthritis. ClinicalTrials.gov. 2011. http: // clinicaltrials.gov/ct2/show/NCT01430481?term0rosehip& rank01. Accessed July 2012
31. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthr Cartil. 2010; 18(2): 141-9. doi: 10.1016/ j.joca.2009.10.002. First comprehensive review of the biological effects of curcumin on chondrocytes.
32. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci. 2004; 1030: 578-86. doi: 10.1196/annals.1329.067. (Pubitemid 40378956)
33. Shakibaei M, Schulze-Tanzil G, John T, Mobasheri A. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. Ann Anat. 2005; 187(5-6): 487-97. (Pubitemid 41715507)
34. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol. 2007; 73 (9): 1434-45. doi: 10.1016/j.bcp.2007.01.005. (Pubitemid 46452591)
35. Clutterbuck AL, Mobasheri A, Shakibaei M, Allaway D, Harris P. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann N Y Acad Sci. 2009; 1171: 428-35. doi: 10.1111/j.1749-6632.2009.04687.x.
36. Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod. 2006; 69(3): 351-5. doi: 10.1021/ np050327j.
37. Toegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB, et al. Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthr Cartil. 2008; 16(10): 1205-12. doi: 10.1016/ j.joca.2008.01.013.
38. Clutterbuck A, Harris P, Mobasheri A. Comment on: comparison between chondroprotective effects of glucosamine, curcumin and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthr Cartil. 2009; 17(1): 135-6. doi: 10.1016/j.joca.2008.07.006. author reply 7.
39. Mobasheri A, Henrotin Y, Biesalski HK, Shakibaei M. Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceuticals for joint health. Int J Mol Sci. 2012; 13(4): 4202-32. doi: 10.3390/ ijms13044202. A critical review presenting the scientific evidence and rationale for using curcumin and resveratrol as nutraceuticals for arthritis.
40. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008; 75(3): 677-87.
41. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009; 11(6): R165. doi: 10.1186/ar2850.
42. Shakibaei M, Csaki C, Nebrich S, Mobasheri A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol. 2008; 76(11): 1426-39. doi: 10.1016/j.bcp.2008.05.029.
43. Shakibaei M, John T, Seifarth C, Mobasheri A. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann N Y Acad Sci. 2007; 1095: 554-63. doi: 10.1196/annals.1397.060. (Pubitemid 47092487)
44. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008. doi: 10.1038/nri2395.
45. Barry FP. Mesenchymal stem cell therapy in joint disease. Novartis Found Symp. 2003; 249: 86-96. discussion 102, 70-4, 239-41.
46. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007; 213(2): 341-7. doi: 10.1002/jcp.21200. (Pubitemid 47509711)
47. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010; 12: 87-117. doi: 10.1146/ annurev-bioeng-070909-105309.
48. Schneider PR, Buhrmann C, Mobasheri A, Matis U, Shakibaei M. Three-dimensional high-density co-culture with primary tenocytes induces tenogenic differentiation in mesenchymal stem cells. J Orthop Res. 2011; 29(9): 1351-60. doi: 10.1002/jor.21400.
49. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 2010; 222(1): 23-32. doi: 10.1002/jcp.21915.
50. Mobasheri A, Csaki C, Clutterbuck AL, RahmanzadehM, Shakibaei M. Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. Histol Histopathol. 2009; 24(3): 347-66.
51. Csaki C, Matis U, Mobasheri A, Shakibaei M. Co-culture of canine mesenchymal stem cells with primary bone-derived osteoblasts promotes osteogenic differentiation. Histochem Cell Biol. 2009; 131(2): 251-66. doi: 10.1007/s00418-008-0524-6.
52. Csaki C, Matis U, Mobasheri A, Ye H, Shakibaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem Cell Biol. 2007; 128(6): 507-20. doi: 10.1007/s00418-007-0337-z. (Pubitemid 350112777)
53. Wehling N, Palmer GD, Pilapil C, Liu F, Wells JW, Muller PE, et al. Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NFkappaB- dependent pathways. Arthritis Rheum. 2009; 60(3): 801-12. doi: 10.1002/art.24352.
54. Buhrmann C, Mobasheri A, Matis U, Shakibaei M. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther. 2010; 12(4): R127. doi: 10.1186/ar3065.
55. Shakibaei M, Shayan P, Busch F, Aldinger C, Buhrmann C, Lueders C, et al. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One. 2012; 7(4): e35712. doi: 10.1371/journal.pone.0035712.
56. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology (Oxford). 2001; 40(7): 779-93.
57. Little CV, Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2001; 1: CD002947. doi: 10.1002/ 14651858.CD002947.
58. Soeken KL, Selected CAM. Therapies for arthritis-related pain: the evidence from systematic reviews. Clin J Pain. 2004; 20(1): 13-8. (Pubitemid 38030114)
59. Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee. ClinicalTrials.gov. 2008. http: //clinicaltrials.gov/ct2/show/NCT00928837 Accessed July 2012
60. Mills SY, Jacoby RK, Chacksfield M, Willoughby M. Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a double-blind study. Br J Rheumatol. 1996; 35(9): 874-8.
61. Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthr Cartil. 2000; 8(1): 9-12. doi: 10.1053/joca.1999.0264. (Pubitemid 30032721)
62. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000; 7(3): 177-83. (Pubitemid 30415074)
63. Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, Rhee HI, et al. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthr Cartil. 2002; 10(6): 471-8. doi: 10.1053/joca.2002.0526. (Pubitemid 34679299)
64. Kim JH, Rhee HI, Jung IH, Ryu K, Jung K, Han CK, et al. SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions. Life Sci. 2005; 77(11): 1181-93. doi: 10.1016/j.lfs.2004.11.040. (Pubitemid 40898319)
65. Teekachunhatean S, Kunanusorn P, Rojanasthien N, Sananpanich K, Pojchamarnwiputh S, Lhieochaiphunt S, et al. Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892]. BMC Complement Altern Med. 2004; 4: 19. doi: 10.1186/1472-6882-4-19. (Pubitemid 41364081)
66. Toegel S, Wu SQ, Otero M, Goldring MB, Leelapornpisid P, Chiari C, et al. Caesalpinia sappan extract inhibits IL1beta-mediated overexpression of matrix metalloproteinases in human chondrocytes. Genes Nutr. 2012; 7(2): 307-18. doi: 10.1007/s12263-011-0244-8.
67. Wu SQ, Otero M, Unger FM, Goldring MB, Phrutivorapongkul A, Chiari C, et al. Anti-inflammatory activity of an ethanolic Caesalpinia sappan extract in human chondrocytes and macrophages. J Ethnopharmacol. 2011; 138(2): 364-72. doi: 10.1016/ j.jep.2011.09.011. First study on the anti-inflammatory properties of Caesalpinia sappan extracts.
68. Park KC, Park EJ, Kim ER, Kim Y, Chung SH, Cho BW, et al. Therapeutic effects of PG201, an ethanol extract from herbs, through cartilage protection on collagenase-induced arthritis in rabbits. Biochem Biophys Res Commun. 2005; 331(4): 1469-77. doi: 10.1016/j.bbrc.2005.04.030. (Pubitemid 40692520)
69. Wang X, CaoY, Pang J, Du J,Guo C, Liu T, et al. Traditional Chinese herbal patch for short-term management of knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2012; 2012: 171706. doi: 10.1155/2012/171706.
70. Majima T, Inoue M, Kasahara Y, Onodera T, Takahashi D, Minami A. Effect of the Japanese herbal medicine, Boiogito, on the osteoarthritis of the knee with joint effusion. Sports Med Arthrosc Rehabil Ther Technol. 2012; 4: 3. doi: 10.1186/1758-2555-4-3.
71. ShakibaeiM,Allaway D, Nebrich S,Mobasheri A. Botanical extracts from Rosehip (Rosa canina), Willow Bark (Salix alba), and Nettle Leaf (Urtica dioica) suppress IL-1beta-induced NF-kappaB activation in Canine Articular Chondrocytes. Evid Based Complement Alternat Med. 2012; 2012: 509383. doi: 10.1155/2012/509383.
72. Biegert C, Wagner I, Ludtke R, Kotter I, Lohmuller C, Gunaydin I, et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. J Rheumatol. 2004; 31(11): 2121-30. (Pubitemid 39453229)
73. Calabrese EJ, Blain R. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol Appl Pharmacol. 2005; 202(3): 289-301. doi: 10.1016/ j.taap.2004.06.023. (Pubitemid 40164282)
74. Calabrese EJ. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol. 2005; 35(6): 463-582.
75. Rattan SI. Hormesis in aging. Ageing Res Rev. 2008; 7(1): 63-78. doi: 10.1016/j.arr.2007.03.002.
76. Rattan SI, Ali RE. Hormetic prevention of molecular damage during cellular aging of human skin fibroblasts and keratinocytes. Ann N Y Acad Sci. 2007; 1100: 424-30. doi: 10.1196/ annals.1395.047. (Pubitemid 47092681)
77. Ernst E. Complementary and alternative medicine in rheumatology. Baillieres Best Pract Res Clin Rheumatol. 2000; 14(4): 731-49. doi: 10.1053/berh.2000.0110. (Pubitemid 32010915)
78. Ernst E. Complementary or alternative therapies for osteoarthritis. Nat Clin Pract Rheumatol. 2006; 2(2): 74-80. doi: 10.1038/ ncprheum0093. (Pubitemid 43239206)
79. Ernst E. Complementary medicine. Curr Opin Rheumatol. 2003; 15 (2): 151-5. (Pubitemid 36250297)
80. Cao Y, Shi Y, Zheng Y, Shi M, Lo SK. Blood-nourishing and hardsoftening capsule costs less in the management of osteoarthritic knee pain: a randomized controlled trial. Evid Based Complement Alternat Med. 2005; 2(3): 363-8. doi: 10.1093/ecam/neh104. (Pubitemid 41253348)
81. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res. 1980; 71: 632-4. (Pubitemid 10058826)
82. Ernst E. Musculoskeletal conditions and complementary/alternative medicine. Best Pract Res Clin Rheumatol. 2004; 18(4): 539-56. doi: 10.1016/j.berh.2004.03.005. (Pubitemid 39145061)
83. Whitehouse MW, Butters DE. Combination anti-inflammatory therapy: synergism in rats of NSAIDs/corticosteroids with some herbal/animal products. Inflammopharmacology. 2003; 11(4): 453-64. doi: 10.1163/156856003322699636. (Pubitemid 38175954)
84. Lawson B, Putnam W, Nicol K, Archibald G, Mackillop J, Conter H, et al. Managing osteoarthritis. Medication use among seniors in the community. Can Fam Physician. 2004; 50: 1664-70. (Pubitemid 40011947)
85. Weiner DK, Ernst E. Complementary and alternative approaches to the treatment of persistent musculoskeletal pain. Clin J Pain. 2004; 20(4): 244-55. (Pubitemid 38802810)